GtoPdb Ligand ID: 8922

Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
risankizumab is an approved drug (FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) [9]. It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Compound class Antibody
Approved drug? Yes (FDA & EMA (2019))
International Nonproprietary Names
INN number INN
10128 risankizumab
ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Database Links
Specialist databases
IMGT/mAb-DB 567
Other databases
GtoPdb PubChem SID 310264703
Search PubMed clinical trials risankizumab
Search PubMed titles risankizumab
Search PubMed titles/abstracts risankizumab